UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

In a report released today, Matthew Weston from UBS upgraded AstraZeneca (AZN – Research Report) to a Buy, with a price target of £142.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca is a company with a turbulent history ... It is based on an adenoviral vector based on a weakened version of the adenovirus that causes a common cold-line illness in chimpanzees ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,745.88 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

After hours: 7:46:25 pm GMT-5 ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...